ArticleFrontiers in oncology2025
Case Report: Rapid resolution of malignant acanthosis nigricans following chemotherapy for cervical cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a 55-year-old non-obese female exhibiting rapidly progressive malignant acanthosis nigricans (MAN) as the initial manifestation, characterized by widespread malodorous skin lesions that preceded the eventual diagnosis of human papillomavirus 16 (HPV16)-positive, poorly differentiated cervical squamous cell carcinoma by four years. Following chemotherapy, both tumor markers and cutaneous manifestations demonstrated rapid regression. However, at the most recent follow-up (August 2025), the patient was hospitalized for management of grade 3 myelosuppression and a secondary pulmonary infection, necessitating temporary suspension of antitumor therapy. This treatment-response correlation provides compelling clinical substantiation for the "tumor-secretory factor-driven" pathogenesis, indicating that MAN may serve as a critical early paraneoplastic signal of HPV-associated gynecologic malignancies and warrant prompt systemic screening upon its recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.